Biopharma SHAKTI Initiative

The Government of India has proposed the Biopharma SHAKTI initiative in the Union Budget 2026–27 with an outlay of ₹10,000 crore over five years.

The scheme aims to strengthen India’s biopharmaceutical sector and position the country as a global biomanufacturing hub.

Objective of the Initiative

The initiative focuses on promoting domestic development and manufacturing of biologics and biosimilars, reducing import dependence, and enhancing India’s competitiveness in the global supply chain. It also aims to support innovation in advanced therapies and improve healthcare outcomes.

Key Features of the Scheme

Financial outlay of ₹10,000 crore (5 years)

Focus on biologics, biosimilars, and advanced therapies

Development of biomanufacturing ecosystem and R&D infrastructure

Creation of clinical trial networks and strengthening regulatory systems

Expansion and upgradation of NIPER institutions for skill development

Significance for India

The initiative marks a strategic shift from India being a generic medicine supplier to becoming a global innovation-driven biopharma hub. It will help India address rising cases of non-communicable diseases (NCDs) such as cancer, diabetes, and autoimmune disorders through advanced biological medicines.

Additional Exam-Relevant Key Facts

Full Form of SHAKTI: Strategy for Healthcare Advancement through Knowledge, Technology and Innovation

Biologics: Complex medicines derived from living organisms (e.g., vaccines, cancer therapies)

Biosimilars: Cost-effective alternatives to biologics with similar efficacy

NIPER: National Institute of Pharmaceutical Education and Research (autonomous institutes under Dept. of Pharmaceuticals)

Regulator: Central Drugs Standard Control Organisation (CDSCO) oversees drug approvals in India

Policy Shift: From “Pharmacy of the World (generics)” → “Biopharma innovation hub”